Human cytomegalovirus (HCMV) is a ubiquitously distributed pathogen that causes severe disease in immunosuppressed patients and infected newborns. The present study was carried out to determine the prevalence of CMV IgM in blood recipient cancer patients. For this purpose, thirty-four serum samples were collected from the blood recipient cancer patients at the Institute of Nuclear Medicine and Oncology Lahore (INMOL) Pakistan. All blood samples were tested by Enzyme-Linked Immunosorbent Assay (ELISA). This study showed that 26.4% of patients were positive for CMV IgM antibody. We suggest screening of blood donor samples for CMV IgM antibody before transfusion and use of other strategies like leucoreduction, filtration, saline-washed RBCs, frozen deglycerolized RBCs could be more appropriate to minimize the risk of transmission of CMV IgM antibody through infected blood to immunosuppressed recipient patients.